Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease

Halina Cichoż-Lach

Abstract

1/2020 vol. 6

Review article

Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease

Halina Cichoż-Lach ¹

Klinika Gastroenterologii z Pracownią Endoskopową, Uniwersytet Medyczny w Lublinie

Online publish date: 2020/04/21

View full text

AMA

Cichoż-Lach H. Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease. Lekarz POZ. 2020;6(1):27-32.

APA

Cichoż-Lach, H. (2020). Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease. Lekarz POZ, 6(1), 27-32.

Chicago

Cichoż-Lach, Halina. 2020. "Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease". Lekarz POZ 6 (1): 27-32.

Harvard

Cichoż-Lach, H. (2020). Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease. Lekarz POZ, 6(1), pp.27-32.

MLA

Cichoż-Lach, Halina. "Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease." Lekarz POZ, vol. 6, no. 1, 2020, pp. 27-32.

Vancouver

Cichoż-Lach H. Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease. Lekarz POZ. 2020;6(1):27-32.

Overlap syndrome drug-induced liver injury (DILI) and non-alcoholic fatty liver disease (NAFLD) is a significant and difficult clinical problem that constitutes a huge challenge for clinicians. Diagnosis of DILI and overlap syndrome DILI/NAFLD and their treatment are presented in this article.

Keywords

drug-induced liver injury, non-alcoholic fatty liver disease, overlap syndrome, diagnosis, treatment

Abstract

Overlap syndrome drug-induced liver injury and non-alcoholic fatty liver disease

Keywords

Share

Indexed in

Integrated with